Shaaban Sherin, Ji Yuan
Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, United States.
ARUP Laboratories, Salt Lake City, Utah, United States.
Front Genet. 2023 Jan 23;14:1099541. doi: 10.3389/fgene.2023.1099541. eCollection 2023.
Pharmacogenomics has been at the forefront of precision medicine during the last few decades. Precision medicine carries the potential of improving health outcomes at both the individual as well as population levels. To harness the benefits of its initiatives, careful dissection of existing health disparities as they relate to precision medicine is of paramount importance. Attempting to address the existing disparities at the early stages of design and implementation of these efforts is the only guarantee of a successful just outcome. In this review, we glance at a few determinants of existing health disparities as they intersect with pharmacogenomics research and implementation. In our opinion, highlighting these disparities is imperative for the purpose of researching meaningful solutions. Failing to identify, and hence address, these disparities in the context of the current and future precision medicine initiatives would leave an already strained health system, even more inundated with inequality.
在过去几十年中，药物基因组学一直处于精准医学的前沿。精准医学在个体和群体层面都具有改善健康结果的潜力。为了利用其举措带来的益处，仔细剖析与精准医学相关的现有健康差异至关重要。在这些努力的设计和实施早期阶段尝试解决现有差异是实现公正成功结果的唯一保证。在本综述中，我们审视了一些现有健康差异的决定因素，因为它们与药物基因组学研究及实施相互交织。我们认为，为了研究有意义的解决方案，突出这些差异势在必行。在当前和未来的精准医学举措背景下，未能识别并解决这些差异将使本已不堪重负的卫生系统更加充满不平等。
